|
EP0932405A4
(en)
|
1996-06-27 |
2001-10-17 |
Smithkline Beckman Corp |
IL-8 RECEPTOR ANTAGONISTS
|
|
AU8673198A
(en)
*
|
1997-07-29 |
1999-02-22 |
Smithkline Beecham Corporation |
Il-8 receptor antagonists
|
|
US7517880B2
(en)
|
1997-12-22 |
2009-04-14 |
Bayer Pharmaceuticals Corporation |
Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
|
|
US7329670B1
(en)
|
1997-12-22 |
2008-02-12 |
Bayer Pharmaceuticals Corporation |
Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas
|
|
US20080300281A1
(en)
*
|
1997-12-22 |
2008-12-04 |
Jacques Dumas |
Inhibition of p38 Kinase Activity Using Aryl and Heteroaryl Substituted Heterocyclic Ureas
|
|
WO1999036069A1
(en)
*
|
1998-01-16 |
1999-07-22 |
Smithkline Beecham Corporation |
Il-8 receptor antagonists
|
|
UY25842A1
(es)
*
|
1998-12-16 |
2001-04-30 |
Smithkline Beecham Corp |
Antagonistas de receptores de il-8
|
|
US20080269265A1
(en)
*
|
1998-12-22 |
2008-10-30 |
Scott Miller |
Inhibition Of Raf Kinase Using Symmetrical And Unsymmetrical Substituted Diphenyl Ureas
|
|
CA2359244C
(en)
|
1999-01-13 |
2013-10-08 |
Bayer Healthcare Llc |
.omega.-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
|
|
US8124630B2
(en)
|
1999-01-13 |
2012-02-28 |
Bayer Healthcare Llc |
ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
|
US7928239B2
(en)
|
1999-01-13 |
2011-04-19 |
Bayer Healthcare Llc |
Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
|
|
US7351834B1
(en)
*
|
1999-01-13 |
2008-04-01 |
Bayer Pharmaceuticals Corporation |
ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
|
EP1140840B1
(en)
|
1999-01-13 |
2006-03-22 |
Bayer Pharmaceuticals Corp. |
-g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
|
JP2003527360A
(ja)
*
|
2000-03-14 |
2003-09-16 |
スミスクライン・ビーチャム・コーポレイション |
Il−8受容体アンタゴニスト
|
|
US6767922B2
(en)
|
2000-03-14 |
2004-07-27 |
Smithkline Beecham Corporation |
IL-8 receptor antagonists
|
|
AR030689A1
(es)
*
|
2000-03-14 |
2003-09-03 |
Smithkline Beecham Corp |
Compuestos de 3-aminosulfonil-2-hidroxifenil urea, composiciones farmaceuticas que los comprenden, y uso de dichos compuestos en la manufactura de medicamentos para tratar enfermedades mediadas por quimioquinas
|
|
US7235576B1
(en)
|
2001-01-12 |
2007-06-26 |
Bayer Pharmaceuticals Corporation |
Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
|
RU2344123C9
(ru)
*
|
2001-04-16 |
2009-05-20 |
Шеринг Корпорейшн |
3,4-дизамещенные циклобутен-1,2-дионы как лиганды схс-хемокинового рецептора
|
|
US7371763B2
(en)
*
|
2001-04-20 |
2008-05-13 |
Bayer Pharmaceuticals Corporation |
Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
|
|
AU2002351196A1
(en)
*
|
2001-12-03 |
2003-06-17 |
Bayer Pharmaceuticals Corporation |
Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers
|
|
EP2324825A1
(en)
|
2002-02-11 |
2011-05-25 |
Bayer Healthcare LLC |
Aryl ureas with angiogenesis inhibiting activity
|
|
SI1580188T1
(sl)
*
|
2002-02-11 |
2012-02-29 |
Bayer Healthcare Llc |
Aril sečnine kot kinazni inhibitorji
|
|
US20030216396A1
(en)
|
2002-02-11 |
2003-11-20 |
Bayer Corporation |
Pyridine, quinoline, and isoquinoline N-oxides as kinase inhibitors
|
|
WO2003068223A1
(en)
*
|
2002-02-11 |
2003-08-21 |
Bayer Corporation |
Aryl ureas with raf kinase and angiogenesis inhibiting activity
|
|
AR041834A1
(es)
*
|
2002-10-29 |
2005-06-01 |
Smithkline Beecham Corp |
Compuesto de difenilurea sustituido con sulfonamida, composicion farmaceutica que lo comprende y su uso para preparar dicha composicion
|
|
WO2004058722A1
(en)
*
|
2002-12-24 |
2004-07-15 |
Arena Pharmaceuticals, Inc. |
Diarylamine and arylheteroarylamine pyrazole derivatives as modulators of 5ht2a
|
|
UY28213A1
(es)
|
2003-02-28 |
2004-09-30 |
Bayer Pharmaceuticals Corp |
Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos.
|
|
DE602004007382T2
(de)
|
2003-05-20 |
2008-04-17 |
Bayer Pharmaceuticals Corp., West Haven |
Diaryl-harnstoffe für durch pdgfr vermittelte krankheiten
|
|
EP1558582B1
(en)
|
2003-07-22 |
2005-12-21 |
Arena Pharmaceuticals, Inc. |
Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
|
|
DK1663978T3
(da)
|
2003-07-23 |
2008-04-07 |
Bayer Pharmaceuticals Corp |
Fluorsubstitueret omega-carboxyaryl-diphenylurinstof til behandling og forebyggelse af sygdomme og lidelser
|
|
CN1926114B
(zh)
*
|
2004-03-23 |
2011-08-24 |
艾尼纳制药公司 |
用于制备经取代n-芳基-n′-′3-(1h-吡唑-5-基)苯基脲及其中间体的方法
|
|
JP2007535565A
(ja)
*
|
2004-04-30 |
2007-12-06 |
バイエル ファーマシューティカルス コーポレーション |
癌の治療に有用な置換ピラゾリル尿素誘導体
|
|
WO2005113534A2
(en)
|
2004-05-12 |
2005-12-01 |
Schering Corporation |
Cxcr1 and cxcr2 chemokine antagonists
|
|
WO2006043950A1
(en)
*
|
2004-10-20 |
2006-04-27 |
Smithkline Beecham Corporation |
Il-8 receptor antagonists
|
|
PE20061130A1
(es)
|
2004-11-19 |
2007-01-05 |
Arena Pharm Inc |
Derivados de 3-fenil-pirazol como moduladores del receptor de serotonina 5-ht2a
|
|
WO2006060762A2
(en)
*
|
2004-12-03 |
2006-06-08 |
Arena Pharmaceuticals, Inc. |
Pyrazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
|
|
CN101160127A
(zh)
*
|
2005-01-19 |
2008-04-09 |
艾尼纳制药公司 |
用于预防或治疗进行性多灶性白质脑病而作为5-ht2a血清素受体调节剂的二芳基和芳基杂芳基脲衍生物
|
|
CA2600008A1
(en)
*
|
2005-02-22 |
2006-11-16 |
Teva Pharmaceutical Industries Ltd. |
Improved process for the synthesis of enantiomeric indanylamine derivatives
|
|
US8097626B2
(en)
|
2006-04-21 |
2012-01-17 |
Glaxosmithkline Llc |
IL-8 receptor antagonists
|
|
AU2007240365B2
(en)
*
|
2006-04-21 |
2011-12-15 |
Glaxosmithkline Llc |
IL-8 receptor antagonists
|
|
USRE45336E1
(en)
|
2006-05-18 |
2015-01-13 |
Arena Pharmaceuticals, Inc. |
Primary amines and derivatives thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto
|
|
EA016675B1
(ru)
|
2006-05-18 |
2012-06-29 |
Арена Фармасьютикалз, Инк. |
Способы получения фенилпиразолов и кристаллическая форма производного фенилпиразола
|
|
WO2007136680A2
(en)
|
2006-05-18 |
2007-11-29 |
Arena Pharmaceuticals, Inc. |
3-pyraz0lyl-benzamide-4-ethers, secondary amines and derivatives thereof as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
|
|
CL2007001829A1
(es)
*
|
2006-06-23 |
2008-01-25 |
Smithkline Beecham Corp |
P-toluensulfonato de n-[4-cloro-2-hidroxi-3-(piperazina-1-sulfonil)fenil]-n-(2-cloro-3-fluorofenil)urea;procedimiento de preparacion;composicion farmaceutica;combinacion farmaceutica;y uso en el tratamiento de una enfermedad mediada por la quiimioquina il-8, tales como asma y epoc.
|
|
TWI415845B
(zh)
|
2006-10-03 |
2013-11-21 |
Arena Pharm Inc |
用於治療與5-ht2a血清素受體相關聯病症之作為5-ht2a血清素受體之調節劑的吡唑衍生物
|
|
US9567327B2
(en)
|
2007-08-15 |
2017-02-14 |
Arena Pharmaceuticals, Inc. |
Imidazo[1,2-a]pyridine derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto
|
|
US20110021538A1
(en)
*
|
2008-04-02 |
2011-01-27 |
Arena Pharmaceuticals, Inc. |
Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
|
|
WO2010062321A1
(en)
|
2008-10-28 |
2010-06-03 |
Arena Pharmaceuticals, Inc. |
Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto
|
|
TR201805216T4
(en)
|
2008-10-28 |
2018-06-21 |
Arena Pharm Inc |
COMPOSITIONS OF A USEFUL 5-HT2A SEROTONINE RECEPTOR MODULATOR FOR THE TREATMENT OF RELATED DISORDERS
|
|
WO2011075596A1
(en)
|
2009-12-18 |
2011-06-23 |
Arena Pharmaceuticals, Inc. |
Crystalline forms of certain 3-phenyl-pyrazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
|
|
HK1245660A1
(zh)
|
2015-06-12 |
2018-08-31 |
Axovant Sciences Gmbh |
有用於预防和治疗rem睡眠行为障碍的二芳基脲和芳基脲衍生物
|
|
WO2017011767A2
(en)
|
2015-07-15 |
2017-01-19 |
Axovant Sciences Ltd. |
Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease
|